Delving into the Latest Updates on Cefozopran Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Cefozopran, Cefozopran hydrochloride (JP17)

+ [4]

Target

PBPs

Action

inhibitors

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesNervous System DiseasesDigestive System Disorders+ [6]

Active Indication

Bacterial InfectionsAdnexitisCholangitis+ [15]

Inactive Indication

(non-specific) purulent meningitisBurnsChronic disease of respiratory system+ [8]

Originator Organization

Takeda Pharmaceutical Co., Ltd.

Active Organization

Teva Takeda Yakuhin Ltd.

Takeda Pharmaceutical Co., Ltd.

Inactive Organization

Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

Japan (01 Aug 1995),

AdnexitisCholangitisCholecystitis+ [14]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC19H18ClN9O5S2

InChIKeyNTJHUKMPVIFDNY-XFDPNJHTSA-N

CAS Registry113981-44-5

View All Structures (2)

对健康受试者进行注射用盐酸头孢唑兰的药代动力学试验，测定头孢唑兰的经时血药浓度，计算头孢唑兰药代动力学参数，了解注射用盐酸头孢唑兰在人体吸收、分布、代谢、消除规律，为制定注射用盐酸头孢唑兰II期临床试验方案提供试验依据。

[Translation]

A pharmacokinetic study of cefazolin hydrochloride for injection was conducted on healthy subjects to determine the time-dependent blood concentration of cefazolin and calculate the pharmacokinetic parameters of cefazolin to understand the absorption, distribution, metabolism, and elimination patterns of cefazolin hydrochloride for injection in the human body, providing an experimental basis for the formulation of a Phase II clinical trial plan for cefazolin hydrochloride for injection.

Start Date14 Sep 2009

Sponsor / Collaborator

Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.

100 Clinical Results associated with Cefozopran Hydrochloride

Login to view more data

100 Translational Medicine associated with Cefozopran Hydrochloride

Login to view more data

100 Patents (Medical) associated with Cefozopran Hydrochloride

Login to view more data

478

Literatures (Medical) associated with Cefozopran Hydrochloride

01 Jan 2025·Current Topics in Medicinal Chemistry

Recent Advances in Nanocatalyzed One-Pot Sustainable Synthesis of Bioactive N, N-Heterocycles with Anticancer Activities: An Outlook of Medicinal Chemistry

Review

Author: Majhi, Sasadhar

N-heterocycles represent a predominant and unique class of organic chemistry. They have received a lot of attention due to their important chemical, biomedical, and industrial uses. Food and Drug Administration (FDA) approved about 75% of drugs containing N-based heterocycles, which are currently available in the market. N-Heterocyclic compounds exist as the backbone of numerous natural products and act as crucial intermediates for the construction of pharmaceuticals, veterinary items, and agrochemicals frequently. Among N-based heterocyclic compounds, bioactive N,N-heterocycles constitute a broad spectrum of applications in modern drug discovery and development processes. Cefozopran (antibiotic), omeprazole (antiulcer), enviradine (antiviral), liarozole (anticancer), etc., are important drugs containing N,N-heterocycles. The synthesis of N,N-heterocyclic compounds under sustainable conditions is one of the most active fields because of their significant physiological and biological properties as well as synthetic utility. Current research is demanding the development of greener, cheaper, and milder protocols for the synthesis of N,N-heterocyclic compounds to save mother nature by avoiding toxic metal catalysts, extensive application of energy, and the excessive use of hazardous materials. Nanocatalysts play a profound role in sustainable synthesis because of their larger surface area, tiny size, and minimum energy; they are eco-friendly and safe, and they provide higher yields with selectivity in comparison to conventional catalysts. It is increasingly demanding research to design and synthesize novel bioactive compounds that may help to combat cancer since the major causes of death worldwide are due to cancer. Hence, the important uses of nanocatalysts for the one-pot synthesis of biologically potent N,N-heterocycles with anticancer activities have been presented in this review.

01 Jan 2025·FUKUSHIMA JOURNAL OF MEDICAL SCIENCE

Drug resistance of Pseudomonas aeruginosa based on the isolation sites and types of gastrointestinal diseases: An observational study

Article

Author: Itazaki, Yujiro ; Horiguchi, Hiroyuki ; Matsukuma, Susumu ; Tsujimoto, Hironori ; Ueno, Hideki ; Okamoto, Koichi ; Takahata, Risa ; Kouzu, Keita ; Kajiwara, Yoshiki ; Fujishima, Sei-ichiro ; Ishibashi, Yusuke ; Sugihara, Takao ; Hamamoto, Taka-aki ; Fujikura, Yuji

INTRODUCTIONWe investigated the drug resistance status of Pseudomonas aeruginosa (P. aeruginosa) focusing on its isolation sites and types of diseases.　Materials and methods: A microbiological laboratory database was searched to identify all clinical cultures positive for P. aeruginosa.　Clinicopathologic features and susceptibility of P. aeruginosa to any antibiotics were evaluated in patients admitted to the division of upper (Upper-GI group) or lower gastrointestinal surgery (Lower-GI group).　In addition, we investigated the susceptibility of P. aeruginosa to any antibiotics based on the isolation site.　Results:P. aeruginosa was frequently detected in the sputum and urine of the Upper-GI and Lower-GI groups, respectively.　Among P. aeruginosa isolates from drain discharge, a significantly higher rate of resistance to imipenem, amikacin, and ciprofloxacin was observed; among P. aeruginosa isolates from wounds, a substantially higher proportion had resistance to imipenem and cefozopran in the Upper-GI group.　However, there was no difference between the two groups in the drug resistance of P. aeruginosa isolated from urine, sputum, blood, and ascites.　P. aeruginosa isolated from sputum showed more resistance to imipenem and ciprofloxacin than those isolated from other sites.　Conclusion: There were significant differences in the drug resistance of P. aeruginosa based on the isolation sites and types of diseases.　.

01 Jan 2025·Journal of Infection and Chemotherapy

Blood culture bottles for culturing cerebrospinal fluid in cases of bacterial meningitis caused by Enterococcus faecalis: A case report

Article

Author: Taguchi, Akira ; Nomura, Toshihito ; Kitagawa, Hiroki ; Kinoshita, Yasuyuki ; Koba, Yumiko ; Hattori, Noboru ; Ohge, Hiroki ; Inada, Shugo ; Omori, Keitaro ; Shigemoto, Norifumi

Pathogen identification is essential for the treatment of bacterial meningitis. However, cerebrospinal fluid (CSF) culture tests are often negative when antimicrobial agents are administered before CSF is collected. Therefore, it is necessary to improve the culturing process for such samples. Here, we report a case of bacterial meningitis where the causative bacteria were detected by inoculating that patient's CSF samples into blood culture bottles. A 52-year-old man developed a fever and headache after undergoing transnasal transsphenoidal surgery for a nonfunctioning pituitary neuroendocrine tumor. He was suspected of having a wound infection, for which he was treated with cefozopran and vancomycin. A CSF test was also performed, owing to persistent fever, and bacterial meningitis was suspected. Although conventional CSF culture tests were negative, CSF cultures using blood culture bottles detected Enterococcus faecalis. The antimicrobial agents were therefore changed to ampicillin and gentamicin, after which the patient's meningitis improved. The blood culture bottles used contained adsorbed polymer beads with antimicrobial neutralizing properties, which likely contributed to the isolation of the bacteria. In addition to conventional cultures, ones done in blood culture bottles may be useful for diagnosing bacterial meningitis via CSF samples-particularly in cases where antimicrobial agents have already been administered.

100 Deals associated with Cefozopran Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02233	Cefozopran Hydrochloride	J01DE03	DB13667

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	Japan	Takeda Pharmaceutical Co., Ltd.	20 Oct 1995
Adnexitis	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Cholangitis	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Cholecystitis	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Cystitis	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Empyema	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Hemorrhagic Septicemia	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Keratitis	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Laryngitis	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Liver Abscess	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Lung Abscess	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Meningitis	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Peritonitis	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Pharyngitis	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Pneumonia	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Pyelonephritis	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Secondary infection	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995
Tonsillitis	Japan	Teva Takeda Yakuhin Ltd.	01 Aug 1995

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Burns	Phase 1	China	Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.	14 Sep 2009
Connective tissue inflammation	Phase 1	China	Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.	14 Sep 2009
Cystitis	Phase 1	China	Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.	14 Sep 2009
Empyema	Phase 1	China	Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.	14 Sep 2009
Intrauterine infection	Phase 1	China	Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.	14 Sep 2009
Laryngitis	Phase 1	China	Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.	14 Sep 2009
Paranasal Sinus Diseases	Phase 1	China	Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.	14 Sep 2009
Pneumonia	Phase 1	China	Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.	14 Sep 2009
Prostatitis	Phase 1	China	Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.	14 Sep 2009
Pyelonephritis	Phase 1	China	Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.	14 Sep 2009